Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

mHealth tool to boost hormone therapy adherence for Latina breast cancer patients

Official title: mHealth to Improve Medication Adherence Among Latina Breast Cancer Patients Experiencing Non-Medical Drivers of Health

Run by The University of Texas Health Science Center at San Antonio · NCT07706127 · Data updated 2026-11-12

A bilingual, culturally tailored smartphone app plus patient navigation is tested to help Latina women on hormone therapy take their medication as prescribed.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment159 (estimated)
SponsorThe University of Texas Health Science Center at San Antonio
Academic / other
Locations1 site (San Antonio, Texas)
StatusRecruiting
StartedSeptember 26, 2025
Main results expectedApril 30, 2028
Study endsApril 30, 2028
Registry record updatedJuly 15, 2026
Trial IDNCT07706127 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

English- or Spanish-speaking Latina women, 18+, on hormone therapy for hormone receptor-positive breast cancer, within 24 months of starting HT, with NMDoH barriers, and owning a smartphone with text and internet access.

Probably not a fit

Patients without non-medical barriers or without access to smartphone/text/internet may receive less or no added benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized approach examines whether the HT Helper app, when combined with patient navigation, improves adherence to hormone therapy among Latina breast cancer patients who face non-medical barriers. The study compares HT Helper plus navigation to navigation alone and to usual care over a four-year period. Participants must be English- or Spanish-speaking Latinas started on hormone therapy within the prior 24 months and must own a smartphone with text and internet access. The trial focuses on those experiencing NMDoH such as income, insurance, or literacy barriers. Outcomes include adherence measures and potential impacts on recurrence risk and mortality related to HT adherence.

Why it matters

Potential benefit: If successful, the intervention could improve HT adherence and potentially reduce breast cancer recurrence and mortality in Latina patients facing non-medical barriers.

How similar studies have gone: Previous work suggests digital health tools can support treatment adherence, though the effectiveness for NMDoH-targeted interventions in this population requires confirmation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

English- or Spanish-speaking Latina patients aged 18 and older who:

a) are diagnosed with hormone receptor-positive breast cancer and prescribed HT; b) within 1 to 24 months of starting HT; c) are experiencing any NMDoH by the Avanzando Center NMDoH Screener; d) are able to read; e) own a smartphone and are able to send and receive text messages and access the Internet; and f) are able to provide informed consent to participate in the study.

Exclusion Criteria:

Not meeting the criteria above, or patients who:

a) are not Latina and are younger than 18 years; b) are not receiving HT treatment; c) with more than 24 months of starting treatment; d) do not experience any NMDoH by the Avanzando Center NMDoH Screener; e) are unable to read; f) do not own a smartphone and are unable to send and receive text messages and access the Internet; g) are unable to respond to text messages and questions or unable to download the study app; h) are unable to provide informed consent due to a mental, emotional, or physical handicap that keeps them from understanding the consent information; i) are unable to see the app and study materials and videos (i.e., are blind, deaf); and j) currently participating in a psychosocial intervention trial or individual/group psychotherapy.

Where it's running

  • The University of Texas Health Science Center at San Antonio
    San Antonio, Texas, United States
    Recruiting

Study contacts

  • Principal investigator: Patricia Chalela, DrPH, MPH — The University of Texas Health Science Center at San Antonio
  • Study coordinator: Study Coordinator
  • Email: HTHelper@uthscsa.edu
  • Phone: 210-567-6523

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.